慢性乙肝合并低水平病毒血症患者肝病风险增加
基于美国行政理赔数据库的倾向评分匹配队列研究显示,慢性乙肝合并低水平病毒血症(HBV-LLV,HBV DNA≤2000 IU/mL)患者发生肝硬化、失代偿、肝细胞癌及复合肝相关结局的风险显著高于无乙肝证据者,且在敏感性分析和第二数据集中得到验证。
要点
- 慢性乙肝合并低水平病毒血症患者肝硬化、失代偿和肝癌风险显著高于无乙肝者。
- 该风险升高在不使用核苷(酸)类似物或随访期间HBV DNA>2000 IU/mL的亚组中依然存在。
- 第二美国数据集验证了肝硬化及复合结局风险升高,提示需加强风险分层与干预。
核心结论
- 慢性乙肝合并低水平病毒血症患者相比无乙肝证据者,肝相关事件风险显著增加。
研究设计与样本
- 使用Optum去标识化Clinformatics Data Mart数据库,构建倾向评分匹配的成人(≥18岁)慢性乙肝低水平病毒血症队列与无慢性乙肝证据对照队列。
- 采用Cox比例风险模型估计肝硬化、失代偿、肝细胞癌、肝移植及复合结局的风险,并计算每100人年的发病率及Poisson 95%CI。
主要发现
- 低水平病毒血症患者肝硬化、失代偿、肝细胞癌及复合结局风险显著高于无乙肝者。
- 在无核苷(酸)类似物治疗或随访期间HBV DNA>2000 IU/mL的亚组敏感性分析中,肝病风险升高持续存在。
- 第二美国数据集(HealthVerity Marketplace)验证了低水平病毒血症患者肝硬化及复合结局风险升高。
关键数值与推荐
- 低水平病毒血症定义为HBV DNA≤2000 IU/mL。
- 研究纳入年龄≥18岁的成人。
临床怎么用
- 对慢性乙肝低水平病毒血症患者应提高肝相关事件风险意识,考虑进一步风险分层和包括早期抗病毒治疗在内的干预策略。
局限性
- 基于美国行政理赔数据,可能存在编码偏倚和未测量混杂。
- 需进一步研究确定风险分层和缓解策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The relationship between hepatitis B virus low-level viraemia (HBV-LLV; HBV DNA ≤ 2000 IU/mL) and the risk of liver-related events is unclear. AIM: To evaluate the relationship between HBV-LLV and subsequent liver-related outcomes in patients with chronic HBV. METHODS: Using Optum's deidentified Clinformatics Data Mart Database, propensity score-matched cohorts of adults (aged ≥ 18 years) with chronic HBV-LLV vs. controls without evidence of chronic HBV were identified. Cox proportional-hazards models were used to estimate the risk of compensated cirrhosis, hepatic decompensation, hepatocellular carcinoma (HCC), liver transplant, and a composite outcome of these four liver-related events among people with HBV-LLV vs. those without HBV. Incidence rates per 100 person-years and corresponding Poisson 95% CIs were calculated for each cohort. RESULTS: Demographic and clinical characteristics were similar between cohorts. The risk of cirrhosis, decompensation, HCC, and the composite outcome was significantly higher for patients with HBV-LLV than for individuals without HBV. Elevated liver disease risk remained in a sensitivity analysis of a subgroup with no nucleos(t)ide analogue treatment or HBV DNA > 2000 IU/mL during follow-up. Elevated risk of cirrhosis and composite outcomes in patients with HBV-LLV was confirmed in a second US dataset (HealthVerity Marketplace). CONCLUSIONS: In this analysis of US administrative claims data, individuals with HBV-LLV had a significantly increased risk of liver-related events compared with those without evidence of HBV. Additional research is needed to identify risk stratification and mitigation strategies, including earlier antiviral treatment.
引用
- Kwo PY, Telep LE, Hong LS, et al. Increased Risk for Liver Disease in Patients With Chronic Hepatitis B Virus Infection and Low-Level Viraemia. Aliment Pharmacol Ther. 2026. PMID: 41920013. doi:10.1111/apt.70613
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。